Use of isavuconazole in mucormycosis: a systematic review

• Published in: BMC infectious diseases Vol. 25; no. 1; pp. 25 - 12
• Main Authors: Gunathilaka, Shobha Sanjeewani, Keragala, Reshani Kaumada, Gunathilaka, Kasun Madhumal, Wickramage, Sujanthi, Bandara, Sachithra Ravindi, Senevirathne, Indika Sanjeewa, Jayaweera, Asela Sampath
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2025; BioMed Central; BMC
• Subjects: Adult; Aged; Amphotericin B; Amphotericin B - administration & dosage; Amphotericin B - therapeutic use; Antifungal agents; Antifungal Agents - administration & dosage; Antifungal Agents - therapeutic use; Antifungals; Antiparasitic agents; Biosynthesis; Case reports; Child; Data management; Debridement; Dosage and administration; Drug dosages; Drug therapy; Drug Therapy, Combination; Female; Grey literature; Heterogeneity; Humans; Infections; Intravenous administration; Isavuconazole; Male; Middle Aged; Mold; Mortality; Mucormycosis; Mucormycosis - drug therapy; Nitriles - therapeutic use; Observational studies; Oral administration; Patients; Posaconazole; Prognosis; Pyridines - adverse effects; Pyridines - therapeutic use; Sterols; Systematic Review; Treatment Outcome; Triazoles - therapeutic use; Sri Lanka; Antifungals; Isavuconazole; Mucormycosis

Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-lin...